{"id":"eptacog-alfa-novoseven","safety":{"commonSideEffects":[{"rate":null,"effect":"Thrombotic events (deep vein thrombosis, pulmonary embolism, myocardial infarction)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hypertension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Eptacog alfa (recombinant human Factor VIIa) binds to tissue factor on cell surfaces and directly activates Factor X to Factor Xa, bypassing the need for upstream factors VIII and IX. This allows patients with deficiencies or inhibitors in the intrinsic pathway to generate thrombin and form stable clots. It is particularly useful in hemophilia A and B patients with inhibitors who cannot use conventional factor replacement therapy.","oneSentence":"Eptacog alfa is a recombinant Factor VIIa that bypasses upstream coagulation defects by directly activating Factor X on the tissue factor pathway to initiate thrombin generation and hemostasis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:29:32.644Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hemophilia A with inhibitors"},{"name":"Hemophilia B with inhibitors"},{"name":"Factor VII deficiency"},{"name":"Glanzmann thrombasthenia with refractoriness to platelet transfusions"},{"name":"Acquired hemophilia"}]},"trialDetails":[{"nctId":"NCT07157423","phase":"PHASE4","title":"A Research Study to See How Safe is Eptacog Alfa When Used to Stop Heavy Bleeding in Women After Giving Birth in India","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-08-26","conditions":"Severe Postpartum Haemorrhage","enrollment":64},{"nctId":"NCT06883240","phase":"","title":"An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-04-29","conditions":"Von Willebrand Disease, Type 3","enrollment":40},{"nctId":"NCT04563520","phase":"PHASE3","title":"SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis","status":"RECRUITING","sponsor":"Emory University","startDate":"2026-03","conditions":"Hemophilia A","enrollment":5},{"nctId":"NCT05662319","phase":"PHASE3","title":"A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-02-01","conditions":"Hemophilia","enrollment":91},{"nctId":"NCT07227246","phase":"PHASE3","title":"Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2","status":"RECRUITING","sponsor":"Joseph Broderick, MD","startDate":"2025-05-06","conditions":"Intracerebral Hemorrhage","enrollment":350},{"nctId":"NCT03496883","phase":"PHASE3","title":"Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Joseph Broderick, MD","startDate":"2021-12-03","conditions":"Intracerebral Hemorrhage","enrollment":860},{"nctId":"NCT04647227","phase":"PHASE4","title":"SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors","status":"RECRUITING","sponsor":"American Thrombosis and Hemostasis Network","startDate":"2021-06-28","conditions":"Hemophilia A With Inhibitor, Hemophilia B With Inhibitor","enrollment":55},{"nctId":"NCT07290634","phase":"","title":"Comparative Outcomes of PCC and Recombinant Activated Factor VIIa in Trauma-Associated Massive Transfusion","status":"RECRUITING","sponsor":"Zeliha Alicikus","startDate":"2026-01-30","conditions":"Thromboembolus, Massive Blood Transfusion; Thrombocytopenia, Trauma","enrollment":4},{"nctId":"NCT07136857","phase":"PHASE2","title":"Eptacog Beta in Glanzmann's (HeT_LFB-Strength-Study_FID531)","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-10-02","conditions":"Glanzmann Thrombasthenia","enrollment":6},{"nctId":"NCT06312475","phase":"PHASE3","title":"Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Alphamab Co., Ltd.","startDate":"2024-01-09","conditions":"Hemophilia A With Inhibitor, Hemophilia B With Inhibitor","enrollment":53},{"nctId":"NCT04023019","phase":"","title":"Treatment of Hemophilia A Patients With FVIII Inhibitors","status":"RECRUITING","sponsor":"Emory University","startDate":"2020-03-17","conditions":"Hemophilia A","enrollment":120},{"nctId":"NCT04543383","phase":"PHASE1","title":"A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-07-27","conditions":"Healthy","enrollment":52},{"nctId":"NCT05695391","phase":"PHASE3","title":"A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures SCOPE HIM","status":"TERMINATED","sponsor":"Laboratoire français de Fractionnement et de Biotechnologies","startDate":"2024-06-07","conditions":"Hemophilia","enrollment":2},{"nctId":"NCT05281718","phase":"EARLY_PHASE1","title":"Factor IX as Adjunctive Therapy to Emicizumab (EMIX)","status":"COMPLETED","sponsor":"Tulane University","startDate":"2022-08-01","conditions":"Hemophilia A","enrollment":12},{"nctId":"NCT06010953","phase":"PHASE1, PHASE2","title":"SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment","status":"COMPLETED","sponsor":"Jiangsu Gensciences lnc.","startDate":"2023-10-12","conditions":"Male, Hemophilia A With Inhibitor, Hemophilia B With Inhibitor","enrollment":24},{"nctId":"NCT05904210","phase":"","title":"Retrospective Experience Assessing the Real-World Utilization and Effectiveness of SEVENFACT®","status":"COMPLETED","sponsor":"Laboratoire français de Fractionnement et de Biotechnologies","startDate":"2023-11-07","conditions":"Hemophilia","enrollment":17},{"nctId":"NCT04595617","phase":"NA","title":"Anti-αIIbβ3 Immunization in Glanzmann Thrombasthenia: Prevalence and Associated Risk Factors: Thrombasthenia Anti-αIIbβ3 Antibodies Study (TAAS)","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2021-01-06","conditions":"Glanzmann Thrombasthenia","enrollment":28},{"nctId":"NCT01830712","phase":"","title":"A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With Inhibitors","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-04","conditions":"Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":15},{"nctId":"NCT01561391","phase":"PHASE4","title":"Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"1998-04","conditions":"Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":36},{"nctId":"NCT04789954","phase":"EARLY_PHASE1","title":"Study on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibitors","status":"COMPLETED","sponsor":"AryoGen Pharmed Co.","startDate":"2020-12-29","conditions":"Hemophilia A With Inhibitor, Hemophilia B With Inhibitor","enrollment":14},{"nctId":"NCT04723979","phase":"","title":"NovoSeven® in Severe Postpartum Haemorrhage - Experiences From UK, DK, FR, NL","status":"COMPLETED","sponsor":"Leiden University Medical Center","startDate":"2020-05-01","conditions":"Post Partum Hemorrhage","enrollment":3322},{"nctId":"NCT05298826","phase":"","title":"Recombinant Factor VII for Intractable Postpartum Haemorrhage","status":"COMPLETED","sponsor":"Aljazeera Hospital","startDate":"2019-06-01","conditions":"Post Partum Hemorrhage","enrollment":41},{"nctId":"NCT02448680","phase":"PHASE3","title":"A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa","status":"COMPLETED","sponsor":"Laboratoire français de Fractionnement et de Biotechnologies","startDate":"2015-12-07","conditions":"Hemophilia A With Inhibitors, Hemophilia B With Inhibitors","enrollment":25},{"nctId":"NCT02548143","phase":"PHASE3","title":"LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures","status":"COMPLETED","sponsor":"Laboratoire français de Fractionnement et de Biotechnologies","startDate":"2016-08-25","conditions":"Hemophilia","enrollment":12},{"nctId":"NCT03372993","phase":"","title":"Prospective, Non-interventional Study to Evaluate Immunogenicity of AryoSeven","status":"COMPLETED","sponsor":"AryoGen Pharmed Co.","startDate":"2016-06-13","conditions":"Hemophilia A With Inhibitor, Hemophilia B With Inhibitor, Factor VII Deficiency","enrollment":200},{"nctId":"NCT04548791","phase":"PHASE1, PHASE2","title":"Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders","status":"TERMINATED","sponsor":"Catalyst Biosciences","startDate":"2021-05-17","conditions":"Factor VII Deficiency, Glanzmann Thrombasthenia, Hemophilia A With Inhibitor","enrollment":19},{"nctId":"NCT04489537","phase":"PHASE3","title":"Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B","status":"TERMINATED","sponsor":"Catalyst Biosciences","startDate":"2021-05-04","conditions":"Hemophilia A With Inhibitor, Hemophilia B With Inhibitor","enrollment":18},{"nctId":"NCT03196284","phase":"PHASE2","title":"A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-08-10","conditions":"Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":26},{"nctId":"NCT03407651","phase":"PHASE2","title":"Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B","status":"COMPLETED","sponsor":"Catalyst Biosciences","startDate":"2017-12-18","conditions":"Hemophilia A With Inhibitor, Hemophilia B With Inhibitor","enrollment":11},{"nctId":"NCT04072237","phase":"PHASE1","title":"Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia","status":"COMPLETED","sponsor":"Catalyst Biosciences","startDate":"2019-09-24","conditions":"Hemophilia A, Hemophilia B, Hemophilia A With Inhibitor","enrollment":11},{"nctId":"NCT02622321","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-11-18","conditions":"Hemophilia A","enrollment":113},{"nctId":"NCT02418793","phase":"PHASE1","title":"A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B","status":"COMPLETED","sponsor":"OPKO Health, Inc.","startDate":"2015-05","conditions":"Hemophilia A, Hemophilia B","enrollment":27},{"nctId":"NCT01757405","phase":"PHASE3","title":"Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2013-02-20","conditions":"Hemophilia A, Hemophilia B","enrollment":40},{"nctId":"NCT04768699","phase":"PHASE1","title":"Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia.","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-12-01","conditions":"Hemophilia A With Inhibitor, Hemophilia B With Inhibitor","enrollment":24},{"nctId":"NCT03079063","phase":"PHASE3","title":"Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII Deficiency","status":"COMPLETED","sponsor":"AryoGen Pharmed Co.","startDate":"2017-03-01","conditions":"Factor VII Deficiency","enrollment":24},{"nctId":"NCT03935334","phase":"PHASE3","title":"Clinical Trial Comparing a Biosimilar Eptacog Alfa With Novoseven, in Patients With Hemophilia With Inhibitors","status":"COMPLETED","sponsor":"AryoGen Pharmed Co.","startDate":"2018-07-23","conditions":"Hemophilia A or B With Inhibitor","enrollment":48},{"nctId":"NCT04444856","phase":"","title":"Clinical Outcomes of NovoSeven® Treatment in Severe Postpartum Haemorrhage - a Study at the University Hospital of Bern","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-06-29","conditions":"Severe Postpartum Haemorrhage","enrollment":225},{"nctId":"NCT04424563","phase":"","title":"Activated Factor Seven in Traumatic Retro Peritoneal Hematoma","status":"COMPLETED","sponsor":"King Abdul Aziz Specialist Hospital","startDate":"2017-05-05","conditions":"Traumatic Bleeding","enrollment":80},{"nctId":"NCT02919800","phase":"PHASE1","title":"A Single-dose, Dose-escalation Study of a Long-acting MOD-5014 in Healthy Adult Male","status":"COMPLETED","sponsor":"OPKO Health, Inc.","startDate":"2017-01-22","conditions":"Hemophilia A or B With Inhibitors","enrollment":32},{"nctId":"NCT02484638","phase":"PHASE2, PHASE3","title":"Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors","status":"TERMINATED","sponsor":"CSL Behring","startDate":"2015-07-23","conditions":"Hemophilia A With Inhibitors, Hemophilia B With Inhibitors","enrollment":25},{"nctId":"NCT03287999","phase":"","title":"Inter Individual Variability in Initiation Pathway Activation and Regulation and Phenotypic Heterogeneity in Patients With Haemophilia A and B","status":"UNKNOWN","sponsor":"Royal Free Hospital NHS Foundation Trust","startDate":"2017-09-19","conditions":"Haemophilia","enrollment":250},{"nctId":"NCT02541942","phase":"PHASE2","title":"Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-04-03","conditions":"Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":19},{"nctId":"NCT03251547","phase":"","title":"Recombinant Activated Factor VII in the Management of Massive Bleeding in Hospital Universiti Sains Malaysia","status":"COMPLETED","sponsor":"Universiti Sains Malaysia","startDate":"2017-08-21","conditions":"Massive Hemorrhage, Massive Blood Loss, Massive Blood Transfusion; Thrombocytopenia","enrollment":76},{"nctId":"NCT01359202","phase":"PHASE2","title":"\"Spot Sign\" Selection of Intracerebral Hemorrhage to Guide Hemostatic Therapy","status":"COMPLETED","sponsor":"Dr. David Gladstone","startDate":"2011-05","conditions":"Stroke","enrollment":50},{"nctId":"NCT00951405","phase":"PHASE2","title":"Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-09-01","conditions":"Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":23},{"nctId":"NCT02900690","phase":"","title":"Health Economics Evaluation of the Management of Severe Postpartum Hemorrhage: Comparison of Recombinant Activated Factor VII Strategy to the Reference Strategy","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2010-04-22","conditions":"Health Care Cost, Post Partum Haemorrhage","enrollment":84},{"nctId":"NCT00810888","phase":"PHASE2","title":"The Spot Sign for Predicting and Treating ICH Growth Study","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2010-11","conditions":"Intracerebral Hemorrhage","enrollment":92},{"nctId":"NCT01876745","phase":"","title":"A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-10-07","conditions":"Congenital Bleeding Disorder, Glanzmann's Disease","enrollment":4},{"nctId":"NCT02020369","phase":"PHASE3","title":"Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors","status":"COMPLETED","sponsor":"rEVO Biologics","startDate":"2014-04","conditions":"Hemophilia A With Inhibitors, Hemophilia B With Inhibitors","enrollment":27},{"nctId":"NCT01392547","phase":"PHASE3","title":"Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-07","conditions":"Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":72},{"nctId":"NCT01439971","phase":"PHASE1","title":"Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia","status":"COMPLETED","sponsor":"Catalyst Biosciences","startDate":"2011-12","conditions":"Hemophilia A","enrollment":29},{"nctId":"NCT02470871","phase":"PHASE1","title":"Study of the Pharmacokinetics and Safety of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) in Patients With Congenital Factor VII Deficiency","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2015-07","conditions":"Congenital Coagulation Factor VII Deficiency","enrollment":9},{"nctId":"NCT01542619","phase":"PHASE1","title":"A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2012-03","conditions":"Healthy","enrollment":40},{"nctId":"NCT00486278","phase":"PHASE2","title":"Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-06","conditions":"Congenital Bleeding Disorder, Haemophilia A, Haemophilia B","enrollment":51},{"nctId":"NCT01586936","phase":"","title":"Non-Interventional Study of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"1999-03-10","conditions":"Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":9},{"nctId":"NCT01564563","phase":"PHASE2","title":"Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2002-06-28","conditions":"Acquired Bleeding Disorder, Bleeding During/Following Surgery","enrollment":11},{"nctId":"NCT01579955","phase":"","title":"Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal Clinical Practice","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"1999-03-10","conditions":"Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":321},{"nctId":"NCT01579968","phase":"","title":"Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors When Undergoing Surgery","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"1999-03-10","conditions":"Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":86},{"nctId":"NCT01561417","phase":"PHASE1","title":"Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-04","conditions":"Acquired Bleeding Disorder, Acquired Haemophilia, Congenital Bleeding Disorder","enrollment":28},{"nctId":"NCT00426803","phase":"PHASE2","title":"Recombinant Factor VIIa in Acute Intracerebral Haemorrhage","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-08","conditions":"Acquired Bleeding Disorder, Intracerebral Haemorrhage","enrollment":400},{"nctId":"NCT01563458","phase":"PHASE2","title":"Safety and Efficacy of Activated Recombinant Human Factor VII in Patients Undergoing Orthotopic Liver Transplantation","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-08","conditions":"Acquired Bleeding Disorder, Bleeding During/Following Surgery","enrollment":208},{"nctId":"NCT00102037","phase":"PHASE2","title":"Use of Activated Recombinant FVII in Spinal Surgery","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-07","conditions":"Acquired Bleeding Disorder, Spinal Fusion","enrollment":50},{"nctId":"NCT01562821","phase":"PHASE2","title":"Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatectomy","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-07","conditions":"Acquired Bleeding Disorder, Cirrhosis","enrollment":235},{"nctId":"NCT01563445","phase":"PHASE2","title":"Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-11","conditions":"Acquired Bleeding Disorder, Intracerebral Haemorrhage","enrollment":40},{"nctId":"NCT01563471","phase":"PHASE1","title":"Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy Volunteers","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-10","conditions":"Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":39},{"nctId":"NCT01563523","phase":"PHASE2","title":"Efficacy and Safety of Activated Recombinant Human Factor VII in Severely Injured Trauma Patients","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-03","conditions":"Acquired Bleeding Disorder, Trauma","enrollment":283},{"nctId":"NCT00154492","phase":"PHASE2","title":"Use of NovoSeven® in Active Variceal Bleeding","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-04","conditions":"Acquired Bleeding Disorder, Cirrhosis","enrollment":265},{"nctId":"NCT01601457","phase":"PHASE2","title":"Activated Recombinant Human Factor VII in Pelvic-acetabular Fracture Reconstruction","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-09","conditions":"Acquired Bleeding Disorder, Trauma","enrollment":48},{"nctId":"NCT01566786","phase":"PHASE2","title":"Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII in Acute Intracerebral Haemorrhage","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-08","conditions":"Acquired Bleeding Disorder, Intracerebral Haemorrhage","enrollment":48},{"nctId":"NCT01562574","phase":"PHASE3","title":"Activated Recombinant Human Factor VII Following Cardiac Bypass Surgery for Paediatric Congenital Heart Disease","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-01","conditions":"Acquired Bleeding Disorder, Cardiac Surgery Requiring Cardiopulmonary Bypass","enrollment":82},{"nctId":"NCT00123591","phase":"PHASE2","title":"Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects With Traumatic Brain Injury","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-01","conditions":"Acquired Bleeding Disorder, Trauma","enrollment":96},{"nctId":"NCT00571584","phase":"PHASE4","title":"High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-11","conditions":"Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":24},{"nctId":"NCT00127283","phase":"PHASE3","title":"Recombinant Factor VIIa in Acute Intracerebral Haemorrhage","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-05","conditions":"Acquired Bleeding Disorder, Intracerebral Haemorrhage","enrollment":829},{"nctId":"NCT00104455","phase":"PHASE1","title":"Dose Response to Recombinant Factor VIIa When Administered for Bleed","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-06","conditions":"Congenital Bleeding Disorder, Healthy","enrollment":64},{"nctId":"NCT00108797","phase":"PHASE4","title":"Trial of NovoSeven® in Haemophilia - Joint Bleeds","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-09","conditions":"Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":42},{"nctId":"NCT00108758","phase":"PHASE2","title":"Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-03","conditions":"Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":23},{"nctId":"NCT01561352","phase":"PHASE2","title":"Efficacy and Safety of Activated Recombinant Human Factor VII in Refractory Haemorrhagic Cystitis","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-09","conditions":"Other Haemostasis Disorder, Haemorrhagic Cystitis","enrollment":7},{"nctId":"NCT01562587","phase":"PHASE1","title":"Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-09","conditions":"Congenital Bleeding Disorder, Haemophilia A, Haemophilia B","enrollment":18},{"nctId":"NCT00154427","phase":"PHASE2","title":"Use of Activated Recombinant Human Factor VII in Cardiac Surgery","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2004-08","conditions":"Acquired Bleeding Disorder, Cardiac Surgery Requiring Cardiopulmonary Bypass","enrollment":172},{"nctId":"NCT00703911","phase":"","title":"Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-03","conditions":"Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":102},{"nctId":"NCT01601613","phase":"PHASE2","title":"Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-07","conditions":"Acquired Bleeding Disorder, Dengue Haemorrhagic Fever","enrollment":28},{"nctId":"NCT01562158","phase":"PHASE2","title":"Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-04","conditions":"Acquired Bleeding Disorder, Bleeding During/Following Surgery","enrollment":100},{"nctId":"NCT00882778","phase":"","title":"PROPACT: Retrospective Prophylaxis Patient Case Collection","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-04","conditions":"Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":86},{"nctId":"NCT00697320","phase":"","title":"Observational Study on the Efficacy and Safety of NovoSeven® During \"Real-life\" Usage in Germany","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-06","conditions":"Congenital Bleeding Disorder, Congenital FVII Deficiency, Glanzmann's Disease","enrollment":64},{"nctId":"NCT01561937","phase":"PHASE1","title":"Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-01","conditions":"Haemostasis, Healthy","enrollment":127},{"nctId":"NCT01561950","phase":"PHASE1","title":"Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2008-05","conditions":"Haemostasis, Healthy","enrollment":91},{"nctId":"NCT01561924","phase":"PHASE1","title":"Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-11","conditions":"Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":17},{"nctId":"NCT00266006","phase":"PHASE2","title":"Factor VIIa in Acute Intracerebral Haemorrhage","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-01","conditions":"Acquired Bleeding Disorder, Intracerebral Haemorrhage","enrollment":90},{"nctId":"NCT00710619","phase":"","title":"Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-06","conditions":"Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":52},{"nctId":"NCT00853086","phase":"","title":"Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia Database","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-01","conditions":"Congenital Bleeding Disorder, Haemophilia A, Haemophilia B","enrollment":139},{"nctId":"NCT00243243","phase":"PHASE3","title":"Effect of rFVIIa on Peri-operative Blood Loss in Patients Undergoing Major Burn","status":"COMPLETED","sponsor":"United States Army Institute of Surgical Research","startDate":"2006-01","conditions":"Burns","enrollment":20},{"nctId":"NCT00951873","phase":"PHASE1","title":"A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Recombinant Human Factor VII in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-07","conditions":"Congenital Bleeding Disorder, Haemophilia A, Haemophilia B","enrollment":38},{"nctId":"NCT00922792","phase":"PHASE1","title":"Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and B","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-06","conditions":"Congenital Bleeding Disorder, Haemophilia A, Haemophilia B","enrollment":8},{"nctId":"NCT01562457","phase":"PHASE1","title":"Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-11","conditions":"Congenital Bleeding Disorder, Haemophilia A, Haemophilia B","enrollment":30},{"nctId":"NCT01856751","phase":"","title":"Use of a TGA and TEM in the Assessment of the Efficacy of Treatment With APCC or rFVIIa","status":"UNKNOWN","sponsor":"Stowarzyszenie Pomocy Chorym na Zakrzepicę i Skazy Krwotoczne Thrombus","startDate":"2014-04","conditions":"Haemophilia","enrollment":80},{"nctId":"NCT01625390","phase":"PHASE2, PHASE3","title":"A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-06","conditions":"Hemophilia A, Hemophilia B","enrollment":10},{"nctId":"NCT01220141","phase":"","title":"Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-11","conditions":"Congenital Bleeding Disorder, Haemophilia A, Haemophilia B","enrollment":51},{"nctId":"NCT00370877","phase":"PHASE4","title":"rhuFVIIa in Post-partum Hemorrhage","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2007-04","conditions":"Postpartum Hemorrhage","enrollment":84},{"nctId":"NCT01476423","phase":"","title":"Observational Registry of the Treatment of Glanzmann's Thrombasthenia","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-01","conditions":"Congenital Bleeding Disorder, Glanzmann's Disease","enrollment":218},{"nctId":"NCT01532661","phase":"","title":"National Registry of rFVIIa (Novoseven) in Haemorrhagic Traumatology","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"2008-04","conditions":"Hemorrhage, Bleeding","enrollment":114}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":273,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Eptacog alfa (NovoSeven)","genericName":"Eptacog alfa (NovoSeven)","companyName":"Novo Nordisk A/S","companyId":"novo-nordisk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Eptacog alfa is a recombinant Factor VIIa that bypasses upstream coagulation defects by directly activating Factor X on the tissue factor pathway to initiate thrombin generation and hemostasis. Used for Hemophilia A with inhibitors, Hemophilia B with inhibitors, Factor VII deficiency.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}